

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER TPP 31435
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 10/031170)
INTERNATIONAL APPLICATION NO. PCT/GB00/02825	INTERNATIONAL FILING DATE 21 July 2000	PRIORITY DATE CLAIMED 21 July 1999	
TITLE OF INVENTION ANTISEPTIC COMPOSITION			
APPLICANT(S) FOR DO/EO/US CLARKE, Paul Douglas			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 			
Items 13 to 20 below concern document(s) or information included:			
<ol style="list-style-type: none"> 13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 22. <input type="checkbox"/> Certificate of Mailing by Express Mail 23. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> a.) Copy of international application as published (WO 01/05226) b.) PCT/IPEA/416 c.) PCT/RO/101 d.) Confirmation Claim for Priority 			

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.101) <div style="font-size: 1.5em; font-weight: bold;">10/031170</div>		INTERNATIONAL APPLICATION NO. PCT/GB00/02825		ATTORNEY'S DOCKET NUMBER TPP 31435	
--	--	---	--	---------------------------------------	--

24. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 <div style="text-align: right; font-weight: bold;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS PTO USE ONLY	
				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input checked="" type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	29 - 20 =	9	x \$18.00	\$162.00	
Independent claims	7 - 3 =	4	x \$84.00	\$336.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,518.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$759.00	
SUBTOTAL =				\$759.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$759.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$759.00	
				Amount to be: refunded	\$
				charged	\$

a. ☒ A check in the amount of \$759.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-4375 A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Thomas P. Pavelko, Esquire
 STEVENS, DAVIS, MILLER & MOSHER, L.L.P.
 1615 L Street, N.W., Suite 850
 Washington, D.C. 20036
 Telephone: (202) 785-0100
 Facsimile: (202) 408-5200 or (202) 408-5080

SIGNATURE
 Thomas P. Pavelko
 NAME
 31,689
 REGISTRATION NUMBER
 January 17, 2002
 DATE
 STEVEN DAVIS MILLER & MOSHER, L.L.P.

THE APPLICANT HEREWITH PETITIONS
 408-5080 TO EXTEND THE TIME FOR
 RESPONSE AS REQUIRED TO MAKE THE
 ATTACHED DOCUMENT TIMELY FILED.
 PLEASE CHARGE THE COST THEREOF
 TO DEPOSIT ACCOUNT 19-4375

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Paul Douglas CLARKE

Attn: Applications

Serial No.: U.S. National Stage Application based on
International Application PCT/GB00/02825
filed 21 July 2000

Filed: January 17, 2002

For: ANTISEPTIC COMPOSITION

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Prior to calculation of the filing fee and examination on the merits, please further amend the
above-identified application as follows:

IN THE ABSTRACT

Please substitute the attached Abstract as a last page of the application. (Attachment I).

IN THE CLAIMS

Please cancel claims 1-5 and 9 without prejudice or disclaimer in favor of new claims 26-31
as follows:

--26. A method of treating a surface by applying an antiseptically, antibioticly, fungicidally
or bactericidally effective amount of p-menthane-3,8-diol (PMD) to the surface.

27. The method of claim 26, wherein the amount is antiseptic against strains of *Staph. aureus*.

28. The method of claim 26, wherein the PMD is a crude or purified natural product.

Inventor: Paul Douglas CLARKE
New U.S. National Stage Application based on
PCT/GB00/02825, filed July 21, 2000

29. The method of claim 28, wherein the PMD is in the form of a PMD-rich extract from lemon eucalyptus oil.

30. The method of claim 26, wherein the PMD is in the form of a mixture of isomers thereof.

31. A composition according to claim 6, wherein the PMD is a crude or purified natural product.

Please amend claims 6-8 and 10-25 as follows. A marked-up copy of the amended claims is enclosed (Attachment II).

6. (Amended) An antiseptic, antibiotic, fungicidal or bactericidal composition which comprises an antiseptic, antibiotic, fungicidal or bactericidal effective amount of p-menthane-3,8-diol (PMD) and a carrier therefor.

7. (Amended) A composition according to claim 6, wherein the carrier is an oil or an organic solvent.

8. (Amended) A composition according to claim 7, wherein the carrier is a mixture of water and an organic solvent miscible therewith.

10. (Amended) A composition according to claim 6, which is the form of household detergent, cleansing or cream composition.

11. (Amended) A composition according to claim 6, which is in a form suitable for medical use.

12. (Amended) A composition according to claim 11, which is in the form of a throat lozenge or pastille, a shampoo, a skin spray, a nasal spray, or in a form for wound irrigation.

Inventor: Paul Douglas CLARKE
New U.S. National Stage Application based on
PCT/GB00/02825, filed July 21, 2000

13. (Amended) A method of sanitizing a surface which comprises applying PMD thereto.
14. (Amended) A method according to claim 13, wherein a PMD composition is applied to the surface.
15. (Amended) A method according to claim 13, wherein the PMD is applied by spraying.
16. (Amended) A method according to claim 13, wherein the PMD is applied by electrostatic deposition.
17. (Amended) A method according to claim 13, wherein the surface is of a human hand or of a glove therefor.
18. (Amended) An article which comprises p-menthane-3,8-diol (PMD) in an amount such that, in use of the article for its intended purpose, the PMD provides an antiseptic, antibiotic, fungicidal or bactericidal effect.
19. (Amended) An article according to claim 18, which comprises a fabric or plastics article impregnated with PMD.
20. (Amended) A method of sanitizing a surface by applying an antiseptically effective amount of p-menthane-3,8-diol (PMD) to the surface by virtue of PMD's antiseptic properties.
21. (Amended) The method according to claim 20, where the surface is on the wall, floor, ceiling or other structural part of a room or building; or an equipment or apparatus; or is a work surface.
22. (Amended) The method according to claim 20, wherein the surface is in or on the body including skin, open wounds and nasal and other passages.

Inventor: Paul Douglas CLARKE
New U.S. National Stage Application based on
PCT/GB00/02825, filed July 21, 2000

23. (Amended) The method according to claim 22, wherein the surface is on the hands.

24. (Amended) A household product comprising p-menthane-3,8-diol (PMD) selected from the group consisting of a detergent, cleanser and cream to provide antiseptic properties.

25. (Amended) A sterile surgical scrub solution which comprises p-menthane-3,8-diol (PMD) as the only or at least one of the antiseptics therein.

Please add new claims 32-35 as follows:

--32. A composition according to claim 6, wherein the PMD is in the form of a PMD-rich extract from lemon eucalyptus oil.

33. A composition according to claim 6, wherein the PMD is in the form of a mixture of isomers thereof.

34. The method of claim 14, wherein the PMD composition is applied by spraying.


35. The method of claim 14, wherein the PMD composition is applied by electrostatic deposition.--

Inventor: Paul Douglas CLARKE
New U.S. National Stage Application based on
PCT/GB00/02825, filed July 21, 2000

REMARKS

The purpose of the forgoing Amendment is to submit the Abstract on a single separate sheet and to delete multiple dependent claims, placing the application in better form for examination under U.S. practice. No new matter is entered.

Respectfully submitted,



Thomas P. Pavelko
Registration No. 31,689

TPP/mat
Attorney Docket No.: TPP 31435

STEVENS, DAVIS, MILLER & MOSHER, L.L.P.
1615 L Street, N.W., Suite 850
Washington, D.C. 20036
Telephone: (202) 785-0100
Facsimile: (202) 408-5200 or (202) 408-5088

Date: January 17, 2002

THE APPLICANT HEREWITH PETITIONS
THE PTO TO EXTEND THE TIME FOR
RESPONSE AS REQUIRED TO MAKE THE
ATTACHED DOCUMENT TIMELY FILED.
PLEASE CHARGE THE COST THEREOF
TO DEPOSIT ACCOUNT 19-4375

STEVEN DAVIS MILLER & MOSHER, L.L.P.

Inventor: Paul Douglas CLARKE
New U.S. National Stage Application based on
PCT/GB00/02825, filed July 21, 2000

ATTACHMENT I

--ABSTRACT

p-Menthane-3,8-diol (PMD) has antiseptic, antibiotic, fungicidal and bactericidal properties.

It is used for these purposes in the form of compositions comprising the PMD and a carrier.--

Inventor: Paul Douglas CLARKE
New U.S. National Stage Application based on
PCT/GB00/02825, filed July 21, 2000

ATTACHMENT II

6. (Amended) An antiseptic, antibiotic, fungicidal or bactericidal composition which comprises an antiseptic, antibiotic, fungicidal or bactericidal effective amount of p-menthane-3,8-diol (PMD) [PMD] and a carrier therefor.

7. (Amended) A composition according to claim 6, wherein the carrier is an oil or an organic solvent.

8. (Amended) A composition according to claim 7, wherein the carrier is a mixture of water and an organic solvent miscible therewith.

10. (Amended) A composition according to claim 6, [7, 8 or 9] which is [a] in the form of household detergent, cleansing or cream composition.

11. (Amended) A composition according to claim 6, [7, 8 or 9,] which is in a form suitable for medical use.

12. (Amended) A composition according to claim 11, which is in the form of a throat lozenge or pastille, a shampoo, a skin spray, a nasal spray, or in a form for wound irrigation.

13. (Amended) A method of sanitizing a surface which comprises applying PMD thereto.

14. (Amended) A method according to claim 13, wherein a PMD composition [as claimed in any of claims 6 to 11] is applied to the surface.

15. (Amended) A method according to claim 13 [or 14], wherein the PMD [or PMD composition] is applied by spraying.

Inventor: Paul Douglas CLARKE
New U.S. National Stage Application based on
PCT/GB00/02825, filed July 21, 2000

16. (Amended) A method according to claim 13, wherein the PMD [or PMD composition] is applied by electrostatic deposition.

17. (Amended) A method according to claim 13, wherein the surface is of a human hand or of a glove therefor.

18. (Amended) An article which [contains or] comprises p-menthane-3,8-diol (PMD) [PMD] in an amount such that, in use of the article for its intended purpose, the PMD provides an antiseptic, antibiotic, fungicidal or bactericidal effect.

19. (Amended) An article according to claim 18, which comprises a fabric or plastics article impregnated with PMD[, or a plastics article impregnated with PMD].

20. (Amended) A method of sanitizing a surface by applying an antiseptically effective amount of p-menthane-3,8-diol (PMD) [The use of PMD for application] to [a] the surface to sanitize [sanitise] the surface by virtue of [its] PMD's antiseptic properties.

21. (Amended) The [use] method according to claim 20, where the surface is on the wall, floor, ceiling or other structural part of a room or building; or an equipment or apparatus; or is a work surface.

22. (Amended) The [use] method according to claim 20, wherein the surface is in or on the body including skin, open wounds and nasal and other passages.

23. (Amended) The [use] method according to claim 22, wherein the surface is on the hands.

Inventor: Paul Douglas CLARKE
New U.S. National Stage Application based on
PCT/GB00/02825, filed July 21, 2000

24. (Amended) A household product comprising p-menthane-3,8-diol (PMD) [The use of PMD in a household product such as] selected from the group consisting of a detergent, cleanser and [or] cream to provide antiseptic properties.

25. (Amended) A sterile surgical scrub solution which comprises p-menthane-3,8-diol (PMD) [PMD] as the only or at least one of the antiseptics therein.

- 1 -

ANTISEPTIC COMPOSITION

The present invention relates to an antiseptic composition.

It is known that a number of natural products have insect repellent properties. Citriadora oil obtained from various species of eucalyptus is one example of such a natural product, citronella oil which is obtained from certain grasses is another. We have previously investigated certain insect repellent natural products and have found that the insect repellent properties are in a fraction rich in p-menthane-3,8-diol (PMD). This is described in our GB-A-2282534. In GB-A-1315625, there is described the use of certain p-menthane diols, but not PMD, to provide a physiological cooling effect.

We have now found, very surprisingly, that PMD not only has the insect repellent properties we have previously described, but also possesses the totally unrelated quality of antiseptic properties. Thus, we have observed antiseptic activity of the compound against certain microbes and, in particular and most importantly, against two strains of multiply resistant *Staphylococcus aureus* (MRSA). It appears, therefore, that PMD will have general antiseptic utility and be particularly useful, at least in respect of certain microbes, as a bactericide as well as being fungicidal and capable of acting as an antibiotic.

- 2 -

According to one aspect of the invention, we provide the use of PMD as an antiseptic. According to a further aspect of the invention, there is provided the use of PMD as an antibiotic. According to a further aspect, the invention provides the use of PMD as a fungicide and/or bactericide

The PMD for use in the present invention may be derived from a natural source or may be synthetic, or a mixture of the two. A preferred source of natural PMD is the lemon eucalyptus plant. Synthetic PMD may be obtained by any route, for example, such as described by Zimmerman and English in J.A.C.S. 75 (1953) pp 2367-2370.

The PMD for use in the present invention may be a substantially pure form of the compound, or a crude extract, for example from a natural source. An example of a crude extract is a PMD-rich extract derived from lemon eucalyptus. The PMD can be produced by cyclisation of citronellal which is present in high concentration in lemon eucalyptus oil (approximately 75% by weight). We have obtained a PMD-rich extract from the lemon eucalyptus oil which includes both geometric isomers of PMD usually at about 64% by weight. The crude extract also includes citronellol and isopulegols plus certain other minor components.


According to a further aspect of the invention, there is provided the use of a PMD-rich extract containing composition, which extract is derived from natural lemon eucalyptus oil, as an antiseptic. We market this crude extract under the trade mark "Citriodiol".

It is known that eucalyptus oils include certain components, such as cineoles, which are known to have antiseptic properties. For the avoidance of doubt, we make no claim to the antiseptic activity of any component, other than PMD when it is derived from a natural source.

A composition for use in accordance with the invention can comprise PMD and a carrier. PMD is poorly soluble in water, so that it is

preferred to use an oil as a carrier, or use a solvent, such as alcohol, for water-based compositions.

It is known that PMD exists in two geometric isomeric forms, namely the cis and trans isomers, and that there are two enantiomers for each geometric isomer.



Our experimental work is based on a substantially pure racemic optical mixture of the cis isomer. It is, however, understood that the claimed activities for PMD are common to all its isomeric forms.

In a further aspect of the invention, the composition for use in the invention comprises only one of the isomers of PMD, with a carrier therefor.

It is a further aspect of the invention that the relative amounts of cis:trans PMD isomers in the compositions for use in the present invention are varied as desired. This can be done by mixing previously separated isomers in the appropriate ratio, or by adjusting the ratio in a mixture of naturally occurring or synthetic source.

In tests we have found that PMD is effective against certain strains of MRSA. In a further aspect, therefore, the invention provides the use of PMD against MRSA.

The uses of the present invention may be adopted in sanitizing a surface, for example in a hospital room or ward. In such cases PMD is applied to the surfaces. The PMD is preferably either in solution or as an emulsion in suitable liquid carriers. Most desirably, the PMD is formulated for spray

application. For example, the PMD or Citriodiol can be dissolved in a suitable solvent or solvent mixture. In a particularly preferred mode of application, the spray is an electrostatic spray. For electrostatic spraying, the solvent or solvent system will need to be appropriate for electrostatic spraying, as will be clear to those skilled in the art. I prefer to use a mixture of conductive and non-conductive solvents to achieve a sprayable solution with the appropriate electrical resistivity for the spray nozzle in question, but suitable single solvents can of course be used. Charged particles of the composition including PMD are projected as a fine mist and because all the particles carry a similar, for example positive, charge they repel each other, but are attracted to an oppositely charged surface. By this means of spraying, a very good coverage of the composition on the surface may be obtained. Devices for electrostatically spraying the composition for use in the invention will be known to the person skilled in the art.

A spray may also be used, for example, for dispensing a composition including PMD onto a hand (or other part) of a person. The actuation of the dispenser may be by means of an infra-red sensor, for example, so that the person need not contact a surface, and thereby risk the transfer of microbes to or from their hand. Electrostatic spray application to a hand may be used, with advantage, where a substantially uniform coverage of antiseptic is particularly important e.g. to a surgeon during "scrubbing up" before surgery. To increase the likelihood of the charged particles covering the skin surface, desirably the electrostatic spray nozzles may be arranged to spray into the interior of a cabinet or container as the hand is introduced therein.

The liquids for applying to a surface, by spraying or otherwise, in accordance with the invention may contain, apart from the solvent(s) and/or other liquid carrier(s), other components as necessary or desirable for the intended purpose. Thus, second or further antiseptics may be included, as may surfactants, fragrances etc. In general, the compositions may be identical to

known compositions for the purpose except that they contain PMD in addition to, or in whole or part substitution for one or more of, the other ingredients. The amount of PMD can vary widely, the greater the amount the greater the effect. We prefer to use up to about 5% by weight of the composition, in general.

PMD may also be included as a component in household detergents, cleansers and creams, for example, washing powders or conditioners and hand gels.

Again, the PMD may be included in what are otherwise standard or known compositions for the purpose concerned. The PMD may be an extra ingredient or in partial or complete replacement of a standard ingredient. The compositions may already contain an antiseptic and the PMD is added to give an extra antiseptic effect.

Furthermore, PMD may be impregnated into household objects which may be prone to microbial infestation and so risk infecting inhabitants, e.g. dishcloths, plastic soap dishes, surfaces used for the preparation of food. For these purposes, the PMD may be included during manufacture of the object, e.g. in mixtures for plastics mouldings or the like, or it may be applied to the object after manufacture, e.g. by soaking dishcloths in PMD. The presence of the PMD at the surface of the object will provide the desired antiseptic effect. This is particularly useful for work surfaces, although of course such surfaces can also be regularly treated with PMD as by spraying or otherwise.

A composition including PMD can also be used in medicine. For example, it can be applied to broken skin, or to internal mucous membranes. It may be an ingredient in throat lozenges or pastilles or other products for ingestion. In this aspect, the invention provides PMD for use as an antiseptic, antibiotic, bactericide or fungicide. In medical uses the PMD may be formulated with the carrier as a cream, or, as mentioned above, as a throat

- 6 -

lozenge or pastille. One cause of dandruff is known to be of fungal origin. PMD may be included as an ingredient in an anti-dandruff shampoo in order to combat the scalp infection, and indeed in non-medicated shampoos and the like. A further specific medical use is based upon the fact that many carriers of staphylococcus bacteria carry the bacterium in their nasal passages. A composition including PMD may be applied to the accessible inner surfaces of the nose in order to control or eliminate bacteria which may cause regular systemic effects. Another specific medical use is in wound irrigation during surgery, e.g. surgery conducted on the peritoneal cavity.

As will be evident to those skilled in the art, there are a very large number of medical uses of PMD not only as an antiseptic but also as an antibiotic, fungicide and bactericide. In general, new formulations for these purposes are not required: it is adequate and satisfactory to take a known or standard composition and include the PMD therein. Alternatively, one or more ingredients may be replaced by the PMD as appropriate. Those skilled in the art will well know the make-up of the various compositions and no further particular description thereof is given here.

PMD is the active ingredient in our "Mosiguard" TM insect repellent. We have conducted tests to show regulatory authorities that PMD is not toxic, and we have marketed our insect repellent for several years and there has been no report of any significant toxicity thereof. Potentially, therefore, the medical uses of PMD may be topical or systemic. Systemic administration may be by way of an oral dosage form or by a parenteral route, such as by intra-venous injection.

In a further aspect, the invention provides the use of PMD in the manufacture of an antiseptic, antibiotic or fungicidal medicament.

In general, PMD is used in accordance with the invention in a wide variety of vehicles, depending on the particular use intended. The vehicles may, for example, include solids, liquids, emulsions, foams and gels.

- 7 -

Typical vehicles include aqueous or alcoholic solutions, oils, fats, fatty acid esters, long chain alcohols and silicone oils, finely divided solids such as starch or talc, cellulosic materials and aerosol propellants. Topical compositions include perfumes, powders and other toiletries, lotions, liniments, oils and ointments, for example. Toiletries generally include after shave lotions, shaving soaps, lipstick, creams, foams, toilet water, deodorants, antiperspirants, solid colognes, toilet soaps, bath oils and salts, shampoos, face and hand creams, cleansing tissues, mouthwashes, eye drops, for example. Medicaments and allied compositions include, for example, ointments, lotions, decongestants and throat lozenges.

The amount of PMD present in the compositions will be selected to give the desired effect but we believe that generally from 0.5 to 5% by weight will be satisfactory. Greater or lesser amounts can be used.

A PMD-rich extract may be obtained from PMD-containing material, such as the leaves of a eucalyptus plant. A preferred source of PMD-rich extract is obtained by stirring eucalyptus citriadora oil derived from the plant with dilute sulphuric acid (usually 5% sulphuric acid), as previously explained in our GB-A-2282534.

In order that the invention may be fully understood, the following Example is given by way of illustration only.

Example 1

Cis PMD MIC/MBC Determination

MIC - minimum inhibitory concentration. This is the concentration of PMD which prevents bacterial growth. A "+" indicates bacterial growth, whereas a "-" indicates that bacterial growth is prevented. Thus, for E. Coli below, the minimum inhibitory concentration is 0.25% PMD in 1.25% ethanol.

MBC - minimum bactericidal concentration. This is the concentration of PMD which kills the bacteria. A "++" indicates live bacteria

- 8 -

are present. Therefore, for E. Coli, the minimum bactericidal concentration is 0.5% PMD in 2.5% ethanol i.e. the concentration immediately above that which does not kill the bacteria.

Cis PMD was dissolved in Absolute Ethanol (0.2 g/ml) to give 20% solution. This was further diluted in water to give 10% in 50% EtOH. 200 µl was added to 0.8 ml Iso-sensitest broth to give a 2% solution in 10% EtOH. Serial 2-fold dilutions in ISB were then carried out and 20 µl E.coli (McFarlane 0.5) were added to each tube and incubated overnight at 37°C. After 18 hours, tubes showing no growth were sub-cultured.

Percentage Concentrations						
Sample	2	1	0.5	0.25	0.125	0.06
E.coli	-	-	-	- +	+ +	+ +
S.aureus (oxford)	-	-	- +	+ +	+ +	+ +
P.aeruginosa	-	-	- +	+ +	+ +	+ +
MRSA 15	-	-	- +	+ +	+ +	+ +
MRSA 16	-	-	- +	+ +	+ +	+ +
S.pyogenes	-	-	-	- +	+ +	+ +
Alcohol concentration	10%	5%	2.5%	1.25%	0.6%	0.3%
Control: Alcohol only /E.coli		+	+	+	+	+

Example 2

A composition of the invention for application to sanitise a surface was made up: by dissolving Citriodiol in a mixture of cyclohexanane (40%) and Exxol D (59%). The composition was applied by electrostatic deposition and by non-electrostatic spraying, to provide a thin antiseptic covering on various surfaces (human skin and work surfaces). The amounts of Citriodiol were varied to provide from about 0.5% to 5.00% PMD. Good antiseptic properties were obtained.

Example 3

A composition of the invention for application to sanitise a surface was made by dissolving Citriodiol in a mixture of:

*	Downal PnB (20%)	667 ml
**	Isopar L (44%)	1473 ml
	Stalox 60 (6%)	194 ml

*Dowanol is a glycol ether/ether acetate solvent.

** Isopar is an isoparaffinic solvent.

The amount of Citriodiol was initially 1000 ml of 30% Citriodiol but other amounts can also be used.

The solution was sprayed electrostatically and non-electrostatically onto various surfaces, e.g. the hands, planar work surfaces, etc. with very satisfactory results.

Example 4

A simple hair shampoo of sodium lauryl ether sulphate (10%) dispersed in water (90%) was mixed with 2% PMD to provide antiseptic properties in the shampoo. Other shampoos, including medicated shampoos for dandruff treatment, can also have PMD incorporated therein to provide an antiseptic, or enhanced antiseptic, effect.

Example 5

Standard proprietary toilet soap formulations can be modified by the inclusion of from ½ to 5% PMD therein to provide an antiseptic or enhanced antiseptic effect. In general, it is not necessary to use more than 5% PMD but greater amounts can be used if desired.

Example 6

A dermatological cream base of composition

	%
sodium citrate	1
cetyl alcohol	2

- 10 -

stearyl alcohol	3
glycerine	12
sodium lauryl sulphate	5
parabens	0.3
petrolatum album to	100%

can be modified in accordance with the invention by including up to about 5% PMD therein to provide antiseptic properties therein.

Example 7

Aqueous nose drops made from a basic aqueous nose drop composition, e.g.

sodium hyaluronate	0.01g
sodium cromoglycate	1.0g
sterile purified water to	100 ml
acid to pH	5.0

can be modified in accordance with the invention to include PMD therein, e.g. 0.5% - 1%, to impart a further antiseptic effect.

Example 8

Standard antiseptic solutions can have their effect enhanced by including therein PMD, in accordance with the invention. The PMD may be added to the standard solutions, or it may be used as a replacement for another antiseptic therein. Antiseptic solutions are generally fairly complex mixtures of antimicrobials, surfactants and solvents, but PMD can be formulated relatively simply in a suitable solvent to provide antiseptic properties.

Example 9

Sterile antiseptic solutions for use internally on the human body, for example in wound sites during surgery, can be made using PMD in place of or in addition to other antiseptics. Such solutions are very effective for wound treatment or ensure antiseptics.

Example 10

Sterile surgical scrubs can be made including PMD as the, or one of the, antiseptics. For example, PMD may be included in a known scrub such as Hibitane which comprises a detergent base of polyoxyethylene-polyoxypropylene block polymer (a nonionic surfactant) and dimethyl lauryl amine oxide (an amphoteric surfactant), and chlorhexidine digluconate as the antiseptic. In general, PMD can be used with, or in place of, known antiseptics such as chlorhexidine and others, as will be clear to those skilled in the art.

CLAIMS:

- 1 The use of p-menthane-3,8-diol (PMD) as an antiseptic, antibiotic, fungicide or bactericide.
- 2 The use of PMD according to claim 1, as an antiseptic against strains of *Staph. aureus*.
- 3 The use according to claim 1 or 2, wherein the PMD is a crude or purified natural product.
- 4 The use according to claim 3, wherein the PMD is in the form of a PMD-rich extract from lemon eucalyptus oil.
- 5 The use according to claim 1 or 2, wherein the PMD is in the form of a mixture of isomers thereof.
- 6 An antiseptic, antibiotic, fungicidal or bactericidal composition which comprises PMD and a carrier therefor.
- 7 A composition according to claim 6, wherein the carrier is an oil or an organic solvent.
- 8 A composition according to claim 7, wherein the carrier is a mixture of water and an organic solvent miscible therewith.
- 9 A composition according to claim 6, 7 or 8, wherein the PMD is as defined in any of claims 3, 4 and 5.

- 13 -

10 A composition according to claim 6, 7, 8 or 9 which is a household detergent, cleansing or cream composition.

11 A composition according to claim 6, 7, 8 or 9, which is in a form suitable for medical use.

12 A composition according to claim 11, which is in the form of a throat lozenge or pastille, a shampoo, a skin spray, a nasal spray, or in a form for wound irrigation.

13 A method of sanitizing a surface which comprises applying PMD thereto.

14 A method according to claim 13, wherein a composition as claimed in any of claims 6 to 11 is applied to the surface.

15 A method according to claim 13 or 14, wherein the PMD or PMD composition is applied by spraying.

16 A method according to claim 13, wherein the PMD or PMD composition is applied by electrostatic deposition.

17 A method according to claim 13, wherein the surface is of a human hand or of a glove therefor.

18 An article which contains or comprises PMD such that, in use of the article for its intended purpose, the PMD provides an antiseptic, antibiotic, fungicidal or bactericidal effect.

- 14 -

19 An article according to claim 18, which comprises a fabric impregnated with PMD, or a plastics article impregnated with PMD.

20 The use of PMD for application to a surface to sanitise the surface by virtue of its antiseptic properties.

21 The use according to claim 20, where the surface is on the wall, floor, ceiling or other structural part of a room or building; or an equipment or apparatus; or is a work surface.

22 The use according to claim 20, wherein the surface is in or on the body including skin, open wounds and nasal and other passages.

23 The use according to claim 22, wherein the surface is on the hands.

24 The use of PMD in a household product such as a detergent, cleanser or cream to provide antiseptic properties.

25 A sterile surgical scrub solution which comprises PMD as the or one of the antiseptics therein.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05226 A1

(51) International Patent Classification⁷: A01N 31/06

(21) International Application Number: PCT/GB00/02825

(22) International Filing Date: 21 July 2000 (21.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9917040.9 21 July 1999 (21.07.1999) GB

(71) Applicant and

(72) Inventor: CLARKE, Paul, Douglas [GB/GB]; 29 Harley Street, London W1N 1DA (GB).

(74) Agents: WAIN, Christopher, Paul et al.; A.A. Thornton & Co., 235 High Holborn, London WC1V 7LE (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTISEPTIC COMPOSITION

(57) Abstract: p-Menthane-3,8-diol (PMD) has antiseptic, antibiotic, fungicidal and bactericidal properties. It is used for these purposes in the form of compositions comprising the PMD and a carrier.

WO 01/05226 A1

01/05226 A1



COMBINED DECLARATION AND POWER OF ATTORNEY FOR UTILITY PATENT APPLICATION (Includes PCT)	Attorney Docket No. TPP 31435
---	----------------------------------

As a below named inventor, I hereby declare that:
My residence, post office address and citizenship are as stated below next to my name;
that
I believe I am the original, first and sole inventor (if only one name is listed below)
or an original, first and joint inventor (if plural inventors are listed below) of the
subject matter which is claimed and for which a patent is sought on the invention entitled:

ANTISEPTIC COMPOSITION

the specification of which (check one)
☐ is attached hereto.

☐ was filed on _____ as Application Serial No. _____ and was amended
on _____. (if applicable)

☒ was filed as PCT International Application No. PCT/GB00/02825 on July 21, 2000, and
was filed in the U.S. National Stage on _____ as U.S. Patent Application No. _____.

I hereby state that I have reviewed and understand the contents of the above identified
specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this
application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I do not know and do not believe the claimed invention was ever known or used in the United
States of America before my or our invention thereof, or patented or described in any printed
publication in any country before my or our invention thereof or more than one year prior to
this application, that the same was not in public use or on sale in the United States of
America more than one year prior to this application, that the invention has not been
patented or made the subject of an inventor's certificate issued before the date of this
application in any country foreign to the United States of America on an application filed
by me or my legal representatives or assigns more than twelve months prior to this
application.

I hereby claim foreign priority benefits under Title 35, United States Code §119 and/or
§365(a)(b) of any foreign application(s) and United States provisional applications for
patent or inventor's certificate listed below and have also identified below any foreign
application for patent or inventor's certificate having a filing date before that of the
application(s) on which priority is claimed:

Prior Foreign and U.S. Provisional Application(s)			Priority Claimed	
<u>9917040.9</u>	<u>Great Britain</u>	<u>21 July 1999</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	Day/Month/Year Filed	Yes	No
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	Day/Month/Year Filed	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 and/or §365(c) of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No. Filing Date

Status
(patented, pending, abandoned)


Application Serial No. Filing Date

Status
(patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith; Stevens, Davis, Miller & Mosher, L.L.P.; Anthony P. Venturino, Reg. No. 31,674; James E. Ledbetter, Reg. No. 28,732; and Thomas P. Pavelko, Reg. No. 31,689. Direct all telephone calls to telephone no. 202-785-0100 and faxes to 202-408-5200.

Address all correspondence to 1615 L Street, N.W., Suite 850, Washington, D.C. 20036.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole, First Inventor <u>Paul Douglas CLARKE</u>	Inventor's Signature 	Date <u>22/1/2002</u>
Residence: <u>London, Great Britain GBN</u>		Citizenship <u>Great Britain</u>
Post Office Address: <u>WIG 9QR, 29 Harley Street, London W1N 1DA Great Britain</u>		